Prostate cancer is the most common cancer for men in the UK,with approximately 40,000 new cases diagnosed every year
A drug for prostate cancer called enzalutamide has been licensed for the treatment of men with advanced prostate cancer whose disease has become resistant to first-line hormonal treatments and has progressed following docetaxel chemotherapy, The licence has been granted based on trial data showing a 37% reduction of the risk of death versus placebo for patients taking enzalutamide during the study. Enzalutamideis are the latest in a new generation of drugs which can prolong and improve the quality of life for men with incurable advanced prostate cancer.
Rowena Bartlett, Chief Executive of the Prostate Cancer Support Federation, said “Until today there have been few treatments for men with advanced prostate cancer and it is fantastic that there is now a new option for patients which both increases life expectancy whilst enabling a patient to feel well enough to make the most of their time with family and friends."
